evorpacept + venetoclax + azacitidine
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, AML, Adult
Trial Timeline
May 5, 2021 → Aug 16, 2023
NCT ID
NCT04755244About evorpacept + venetoclax + azacitidine
evorpacept + venetoclax + azacitidine is a phase 1 stage product being developed by ALX Oncology for Acute Myeloid Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT04755244. Target conditions include Acute Myeloid Leukemia, AML, Adult.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04755244 | Phase 1 | Terminated |
Competing Products
20 competing products in Acute Myeloid Leukemia